Ironwood Pharma (IRWD) Tops Q4 EPS by 6c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2019 Results, Exceeding Full Year 2019 Guidance; Provides Full Year 2020 Guidance
February 13, 2020 7:00 AM EST2019 revenue of $428 million, driven primarily by U.S. LINZESS® (linaclotide) collaboration revenue
GAAP net income from continuing operations of $59 million and adjusted EBITDA from continuing operations of $148 million for the full year 2019
2020 total revenue and adjusted EBITDA guidance incorporates previously amended agreements with Astellas and AstraZeneca
Data readouts from MD-7246 Phase II trial and IW-3718 Phase III trials expected in 2020
BOSTON--(BUSINESS... More
